Veracyte (VCYT) Misses Q4 EPS by 30c ; Offers Guidance

Veracyte (NASDAQ: VCYT) reported Q4 EPS of ($0.39), $0.30 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $98.2 million versus the consensus estimate of $91.29 million.

GUIDANCE:

Veracyte sees FY2024 revenue of $394-402 million, versus the consensus of $392.7 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial